CervoMed Inc (CRVO) Stock Forecast & Price Target

CervoMed is compelling because neflamapimod is showing a coherent mechanistic story across DLB and nfvPPA, with MRI, biomarker, and clinical signals suggesting it may address synaptic dysfunction and basal forebrain atrophy rather than only symptoms. The 159-patient RewinD-LB dataset, along with durable right basal forebrain volume stabilization over 48 weeks and improved connectivity measures, strengthens confidence that the program can meaningfully alter disease biology, while the ongoing Phase 2a nfvPPA study with 25 participants offers another near-term catalyst. Fundamental risk is also falling as the FDA removed the plasma exposure limit, the company secured a new 50mg tablet and controlled manufacturing process, and PK modeling supports a 100mg BID regimen with higher trough exposure and better dosing flexibility for future pivotal development.

CervoMed is fundamentally challenged by reliance on a single clinical asset, neflamapimod, after RewinD-LB failed to replicate earlier Phase 2a benefits in the placebo-controlled phase, undermining confidence in the program’s core efficacy narrative. The company’s own analysis suggests the miss was driven by a higher-than-targeted share of patients with Alzheimer’s co-pathology and suboptimal plasma exposure, while only narrow subgroups showed benefit, leaving the broader commercial and regulatory case uncertain. Financially, CervoMed had $24.9M in cash, cash equivalents, and marketable securities at the midpoint of 2026, reported a 2Q26 net loss of $0.64 per share, and faces medium-term dilution risk if it cannot execute a timely Phase 3 trial and secure positive pivotal data.